XML 25 R15.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS	6 Months Ended
SUBSEQUENT EVENTS	Jun. 30, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	10. SUBSEQUENT EVENTS On July 24, 2018, AbbVie received approval from the FDA for ORILISSA^TM (elagolix) for the management of moderate to severe endometriosis pain in women. This approval generated a $40.0 million event-based payment to the Company in the third quarter of 2018, which is payable by AbbVie within 30 days of the event and will be recognized as revenue by the Company in the third quarter of 2018.